BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:29 PM
Oct 01, 2012
 |  BC Extra  |  Top Story

Astellas, J&J in autoimmune deal

Astellas Pharma Inc. (Tokyo:4503) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights, excluding Japan, to develop and commercialize autoimmune product ASP015K....

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >